|
AHA late breaking abstract
|
8
|
Resverlogix Corp.
|
Nov 10, 2019 11:00AM
|
|
Re: Optimistic
|
8
|
Resverlogix Corp.
|
Oct 14, 2021 06:17PM
|
|
Re: ... unfinished business
|
8
|
Zenith Epigenetics
|
Nov 01, 2018 10:37AM
|
|
Re: Farxiga (SGLT2i) approved for CKD patients with AND without T2D
|
8
|
Resverlogix Corp.
|
May 03, 2021 06:40PM
|
|
Re: Is this bad for RVX but right, on the money?
|
8
|
Resverlogix Corp.
|
Apr 25, 2020 07:58AM
|
|
Re: Market Woes
|
8
|
Resverlogix Corp.
|
May 02, 2022 09:31PM
|
|
Re: AGM Oct 26, 2023
|
8
|
Zenith Epigenetics
|
Aug 13, 2023 10:14AM
|
|
Re: Timing is everything !!!
|
8
|
Resverlogix Corp.
|
Feb 25, 2016 10:26AM
|
|
Re: Apabetalone’s Positive Impact on COVID-19 in Human Lung Cells Published in Biomedicines
|
8
|
Resverlogix Corp.
|
Apr 21, 2021 10:47AM
|
|
Alpine Immune buyout by Vertex
|
8
|
Zenith Epigenetics
|
Apr 11, 2024 11:09AM
|
|
Re: Resverlogix Announces Two New Publications on Apabetalone in Kidney Disease
|
8
|
Resverlogix Corp.
|
Mar 28, 2018 08:00AM
|
|
Re: Lilly to Discontinue Development of Evacetrapib
|
8
|
Resverlogix Corp.
|
Oct 12, 2015 08:12PM
|
|
Re: you won’t see anyone buying this
|
8
|
Zenith Epigenetics
|
Dec 12, 2023 08:57AM
|
|
Re: Deja Vu All Over Again
|
8
|
Resverlogix Corp.
|
Mar 13, 2022 10:25AM
|
|
Re: any increase in SP
|
7
|
Resverlogix Corp.
|
Aug 02, 2024 11:25AM
|
|
Re: Pfizer
|
7
|
Zenith Epigenetics
|
Mar 12, 2024 04:21PM
|
|
Analyst coverage and more promo coverage
|
7
|
Resverlogix Corp.
|
Nov 18, 2017 06:03PM
|
|
New article from EHJ
|
7
|
Resverlogix Corp.
|
Jan 30, 2018 09:18AM
|
|
Re: Time for management to consider shareholder value as well
|
7
|
Resverlogix Corp.
|
Jun 18, 2016 09:01PM
|
|
Re: Nasdaq listing -- Awesome News!!
|
7
|
Resverlogix Corp.
|
Aug 01, 2018 01:53PM
|
